We are analyzing https://link.springer.com/article/10.1007/s00262-006-0216-9.

Title:
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles | Cancer Immunology, Immunotherapy
Description:
SART3-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Twenty-nine SART3-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were first screened for their recognizability by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype+ prostate cancer patients. As a result, five SART3 peptides were frequently recognized by IgG, and two of them—SART3 511-19 and SART3 734-42—efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8+ T cells. These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype+ prostate cancer patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cancer, hlaa, prostate, sart, patients, peptides, cells, peptide, supertype, pbmcs, article, google, scholar, alleles, itoh, ctls, cra, pubmed, cas, peptidespecific, expression, candidates, cytotoxicity, cell, lncap, cytotoxic, harada, iggs, lymphocytes, lines, lncapa, identified, induction, assay, cancerreactive, based, hiv, molecules, reactive, table, protein, sartderived, potential, induce, vaccine, binding, igg, plasma, japan, peptidestimulated,

Topics {✒️}

fitc-conjugated anti-mouse immunoglobulin inducing hla-a24-restricted cytotoxic ctl precursor-oriented vaccines peptide-based anti-cancer vaccine peptide-pulsed unlabeled c1r-a11 hla-a11+ t-cell blasts hla-a3 supertype alleles parathyroid hormone-related protein hiv peptide-pulsed c1r-a11 epithelial cancer-related antigens sart3 tumor-rejection antigen north american african–americans individual peptide side-chains induce peptide-specific cytotoxic induce cancer-reactive cytotoxic prostate cancer-reactive cytotoxic administered ctl-directed peptides measure anti-peptide antibody generate peptide-specific ctls subjects included hla-a11+ enzyme-linked immunosorbent assay detect peptide-specific cytotoxic induce peptide-specific ctls maximum release—spontaneous release overlapping peptide-binding repertoires induce cancer-reactive ctls generating peptide-specific ctls anti-hla-a33 mab thousand 51cr-labeled cells superscript-pre-amplification system stimulated t-cell blasts peptide-specific cellular responses recurrent hormone-refractory peptide-pulsed c1r-a11 peptide-binding motif analyses 51cr-labeled target cells antibodies—anti-hla-a11 hla-a68 molecules belong sart3 peptide-specific igg sart3-derived peptides listed tumor-rejection antigens 0201-restricted ctl epitope rt-pcr-based method anti-cancer vaccine human prostate cancer prostate cancer patients hla-a24 alleles innovative cancer therapy peptide-specific cytotoxic induce peptide-specific

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles
         description:SART3-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Twenty-nine SART3-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were first screened for their recognizability by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype+ prostate cancer patients. As a result, five SART3 peptides were frequently recognized by IgG, and two of them—SART3 511-19 and SART3 734-42—efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8+ T cells. These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype+ prostate cancer patients.
         datePublished:2006-08-26T00:00:00Z
         dateModified:2006-08-26T00:00:00Z
         pageStart:689
         pageEnd:698
         sameAs:https://doi.org/10.1007/s00262-006-0216-9
         keywords:
            Prostate cancer
            SART3
            CTL
            Peptide
            HLA-A3 supertype
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0216-9/MediaObjects/262_2006_216_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0216-9/MediaObjects/262_2006_216_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0216-9/MediaObjects/262_2006_216_Fig3_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Takafumi Minami
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
                     name:Kinki University School of Medicine
                     address:
                        name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Satoko Matsueda
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hiroko Takedatsu
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masahiro Tanaka
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masanori Noguchi
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hirotsugu Uemura
               affiliation:
                     name:Kinki University School of Medicine
                     address:
                        name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kyogo Itoh
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mamoru Harada
               affiliation:
                     name:Kurume University School of Medicine
                     address:
                        name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
                     name:Kurume University School of Medicine
                     address:
                        name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                        type:PostalAddress
                     type:Organization
                     name:Shimane University School of Medicine
                     address:
                        name:Department of Immunology, Shimane University School of Medicine, Izumo, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles
      description:SART3-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Twenty-nine SART3-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were first screened for their recognizability by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype+ prostate cancer patients. As a result, five SART3 peptides were frequently recognized by IgG, and two of them—SART3 511-19 and SART3 734-42—efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8+ T cells. These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype+ prostate cancer patients.
      datePublished:2006-08-26T00:00:00Z
      dateModified:2006-08-26T00:00:00Z
      pageStart:689
      pageEnd:698
      sameAs:https://doi.org/10.1007/s00262-006-0216-9
      keywords:
         Prostate cancer
         SART3
         CTL
         Peptide
         HLA-A3 supertype
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0216-9/MediaObjects/262_2006_216_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0216-9/MediaObjects/262_2006_216_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0216-9/MediaObjects/262_2006_216_Fig3_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Takafumi Minami
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
                  name:Kinki University School of Medicine
                  address:
                     name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Satoko Matsueda
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hiroko Takedatsu
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masahiro Tanaka
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masanori Noguchi
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hirotsugu Uemura
            affiliation:
                  name:Kinki University School of Medicine
                  address:
                     name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kyogo Itoh
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mamoru Harada
            affiliation:
                  name:Kurume University School of Medicine
                  address:
                     name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
                  name:Kurume University School of Medicine
                  address:
                     name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
                     type:PostalAddress
                  type:Organization
                  name:Shimane University School of Medicine
                  address:
                     name:Department of Immunology, Shimane University School of Medicine, Izumo, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kurume University School of Medicine
      address:
         name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kinki University School of Medicine
      address:
         name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kinki University School of Medicine
      address:
         name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Kurume University School of Medicine
      address:
         name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
         type:PostalAddress
      name:Shimane University School of Medicine
      address:
         name:Department of Immunology, Shimane University School of Medicine, Izumo, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Takafumi Minami
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
            name:Kinki University School of Medicine
            address:
               name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Satoko Matsueda
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Hiroko Takedatsu
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Masahiro Tanaka
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Masanori Noguchi
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Hirotsugu Uemura
      affiliation:
            name:Kinki University School of Medicine
            address:
               name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
               type:PostalAddress
            type:Organization
      name:Kyogo Itoh
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
      name:Mamoru Harada
      affiliation:
            name:Kurume University School of Medicine
            address:
               name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
            name:Kurume University School of Medicine
            address:
               name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
               type:PostalAddress
            type:Organization
            name:Shimane University School of Medicine
            address:
               name:Department of Immunology, Shimane University School of Medicine, Izumo, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
      name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Urology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Urology, Kinki University School of Medicine, Osaka, Japan
      name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
      name:Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology, Kurume University School of Medicine, Kurume, Japan
      name:Department of Immunology, Shimane University School of Medicine, Izumo, Japan

External Links {🔗}(107)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.46s.

LINK . SPRINGER . COM {}